BRISTOL MYERS SQUIBB
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT05284890
- Locations
- 🇺🇸
Local Institution - 0001, Madison, Wisconsin, United States
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT05255601
- Locations
- 🇮🇹
Local Institution - 0010, Aviano, Italy
🇮🇹Local Institution - 0007, Bologna, Italy
🇮🇹Azienda Ospedaliero Universitaria Meyer, Florence, Italy
A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer
Completed
- Conditions
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 501
- Registration Number
- NCT05250817
- Locations
- 🇺🇸
RTI Health Solutions, Research Triangle Park, North Carolina, United States
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT05244070
- Locations
- 🇺🇸
Local Institution - 0026, Hackensack, New Jersey, United States
🇺🇸Local Institution - 0007, Boston, Massachusetts, United States
🇺🇸Local Institution - 0005, Birmingham, Alabama, United States
A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 42
- Registration Number
- NCT05236738
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States
A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation
Recruiting
- Conditions
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 720
- Registration Number
- NCT05232643
- Locations
- 🇮🇹
Local Institution - 0001, Milano, MI, Italy
A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 290
- Registration Number
- NCT05218902
- Locations
- 🇨🇳
Local Institution - 0001, Tianjin, Tianjin, China
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
Completed
- Conditions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT05217082
- Locations
- 🇺🇸
Local Institution - 0001, Morrisville, North Carolina, United States
Expanded Access for Anti-IL8
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05210894
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT05209295
- Locations
- 🇦🇷
Hospital Universitario Austral, Pilar, Buenos Aires, Argentina
🇨🇴Instituto Nacional De Cancerologia, Bogota, Cundinamarca, Colombia
🇺🇸University of Iowa, Iowa City, Iowa, United States
© Copyright 2024. All Rights Reserved by MedPath